The biotech community faces mounting challenges from politicization and funding cuts. Researchers issued the Bethesda Declaration urging restoration of NIH grants delayed or terminated under the Trump administration, citing impacts on global scientific progress. Concurrently, the entire CDC vaccine advisory committee was removed and is being reconstituted by HHS Secretary RFK Jr., raising concerns about vaccine policymaking continuity. The disruption occurs amidst critical windows for rare disease drug approvals and digital health advancement, underscoring the fraught regulatory environment shaping biotech’s future.